EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Lebrikizumab Dosed Every 8 Weeks as Maintenance Provides Durable Response in Adolescent Patients With Moderate-toSevere Atopic Dermatitis

Vikash Oza, Alan Irvine, Vivian Laquer, Peter Lio, Elizabeth Swanson, Kim Papp, Louise DeLuca-Carter, Heidi Crane, Hany Elmaraghy, Yuxin Ding, Meihua Qiao, Amy Susan Paller

SKIN The Journal of Cutaneous Medicine · 10.11.2026 · 10 (6) · s834

DOI: 10.25251/31rhrb86 ↗

Kurz gefasst

Fachartikel in der Zeitschrift SKIN The Journal of Cutaneous Medicine, online erschienen am 10.11.2026. Verfasst von Vikash Oza und 11 weiteren Autor:innen. Die Arbeit nennt 2 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

In the maintenance periods of ADvocate1 and ADvocate2, efficacy was consistent between the every 2 weeks and every 4 weeks (Q4W) maintenance dosing regimens, and a high proportion of Week 16 responders in the lebrikizumab withdrawal arm exhibited durable efficacy, suggesting less frequent dosing could maintain effectiveness in atopic dermatitis (AD). An extension to the ADjoin long-term study (ADjoin extension) subsequently evaluated the Q8W interval as a maintenance regimen. In the overall ADjoin extension population, Q8W has been reported to provide clinical responses consistent with Q4W dosing. As approximately 10% of adolescents have AD, this analysis describes whether adolescents in the ADjoin extension had a durable response over 32 weeks of Q4W or Q8W dosing.

Methods

ADjoin extension was a 32-week study that enrolled patients with AD who had completed the 100-week long-term ADjoin study (NCT04392154) after participation in the parent studies. Key eligibility criteria included being adults or adolescents (≥12–

Zitieren

APA

Oza, V., Irvine, A., Laquer, V., Lio, P., Swanson, E., Papp, K., DeLuca-Carter, L., Crane, H., Elmaraghy, H., Ding, Y., Qiao, M., & Paller, A. S. (2026). Lebrikizumab Dosed Every 8 Weeks as Maintenance Provides Durable Response in Adolescent Patients With Moderate-toSevere Atopic Dermatitis. SKIN The Journal of Cutaneous Medicine, 10(6), s834. https://doi.org/10.25251/31rhrb86

Vancouver

Oza V, Irvine A, Laquer V, Lio P, Swanson E, Papp K, et al. Lebrikizumab Dosed Every 8 Weeks as Maintenance Provides Durable Response in Adolescent Patients With Moderate-toSevere Atopic Dermatitis. SKIN The Journal of Cutaneous Medicine. 2026;10(6):s834. doi:10.25251/31rhrb86

BibTeX
@article{Oza2026,
  author = {Oza, Vikash and Irvine, Alan and Laquer, Vivian and Lio, Peter and Swanson, Elizabeth and Papp, Kim and DeLuca-Carter, Louise and Crane, Heidi and Elmaraghy, Hany and Ding, Yuxin and Qiao, Meihua and Paller, Amy Susan},
  title = {Lebrikizumab Dosed Every 8 Weeks as Maintenance Provides Durable Response in Adolescent Patients With Moderate-toSevere Atopic Dermatitis},
  journal = {SKIN The Journal of Cutaneous Medicine},
  year = {2026},
  volume = {10},
  number = {6},
  pages = {s834},
  doi = {10.25251/31rhrb86}
}
Kostenlos starten →